Page 150 - Haematologica July

C. Lam et al.
14. Monaghan KA, Khong T, Burns CJ, Spencer A. The novel JAK inhibitor CYT387 sup- presses multiple signalling pathways, pre- vents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia. 2011;25(12):1891-1899.
15. Li J, Favata M, Kelley JA, et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and revers- es the protective effects of cytokine and stromal cell support. Neoplasia. 2010; 12(1):28-38.
16. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyr- phostin AG490 downregulates the mito- gen-activated protein kinase (MAPK) and signal transducer and activator of transcrip- tion (STAT) pathways and induces apopto- sis in myeloma cells. Br J Hematol. 2000;109(4):823-828.
17. Ramakrishnan V, Kimlinger T, Haug J, et al. TG101209, a novel JAK2 inhibitor, has sig- nificant in vitro activity in multiple myelo- ma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol. 2010;85(9):675-686.
18. Scuto A, Krejci P, Popplewell L, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011; 25(3):538-550.
19. Burger R, Le Gouill S, Tai YT, et al. Janus kinase inhibitor INCB20 has antiprolifera- tive and apoptotic effects on human myelo- ma cells in vitro and in vivo. Mol Cancer Therap. 2009;8(1):26-35.
20. Smith EJ, Olson K, Haber LJ, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015;5:17943.
21. McMillin DW, Delmore J, Weisberg E, et al. Tumor cell-specific bioluminescence plat- form to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010; 16(4):483-489.
22. Wiita AP, Ziv E, Wiita PJ, et al. Global cellu- lar response to chemotherapy-induced apoptosis. eLife. 2013;2:e01236.
23. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):R106.
24. Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucl Acids Res. 2016;44(W1):W90- 97.
25. Fila J, Honys D. Enrichment techniques employed in phosphoproteomics. Amino acids. 2012;43(3):1025-1047.
26. Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, Ma'ayan A. ChEA: transcrip- tion factor regulation inferred from inte- grating genome-wide ChIP-X experiments. Bioinformatics. 2010;26(19):2438-2444.
27. Mi H, Huang X, Muruganujan A, et al. PANTHER version 11: expanded annota- tion data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucl Acids Res. 2017; 45(D1):D183-D189.
28. Nelson EA, Walker SR, Frank DA. Jak/STAT signaling in the pathogenesis and treatment of multiple myeloma. In: Anderson KC, ed. Advances in biology and therapy of multiple myeloma: Volume 1: Basic Science. New York: Springer, 2013: 117-138.
29. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, et al. Interleukin-6-dependent gene expression profiles in multiple myelo- ma INA-6 cells reveal a Bcl-2 family-inde- pendent survival pathway closely associat- ed with Stat3 activation. Blood. 2004; 103(1):242-251.
30. Karjalainen R, Pemovska T, Popa M, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell- induced protection of AML. Blood. 2017; 130(6):789-802.
31. Smith GA, Uchida K, Weiss A, Taunton J. Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling. Nat Chem Biol. 2016;12(5):373-379.
32. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myelopro- liferative neoplasms. Blood. 2010; 115(15):3109-3117.
33. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and pro- teome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367-1372.
34. Leitner A. Enrichment strategies in phos- phoproteomics. Meth Mol Biol. 2016; 1355:105-121.
35. Lachmann A, Ma'ayan A. KEA: kinase enrichment analysis. Bioinformatics. 2009; 25(5):684-686.
36. Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interac- tion potency model. Comp Struct Biotechnol J. 2015;13:504-513.
37. Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexam- ethasone in relapsed/refractory MM. Blood. 2017;130(22):2392-2400.
38. Yokoyama S, Perera PY, Terawaki S, et al. Janus kinase inhibitor tofacitinib shows potent efficacy in a mouse model of autoimmune lymphoproliferative syn- drome (ALPS). J Clin Immunol. 2015; 35(7):661-667.
39. Zlei M, Egert S, Wider D, Ihorst G, Wasch R, Engelhardt M. Characterization of in vitro growth of multiple myeloma cells. Exp Hemaol. 2007;35(10):1550-1561.
40. Shain KH, Yarde DN, Meads MB, et al. Beta1 integrin adhesion enhances IL-6- mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and prolifera- tion. Cancer Res. 2009;69(3):1009-1015.
41. Burger R, Gunther A, Klausz K, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017;102(2):381-390.
42. Burger R, Guenther A, Bakker F, et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine- regulated tumor model for plasmacytoma. Hematol J. 2001;2(1):42-53.
43. Tenhumberg S, Waetzig GH, Chalaris A, et al. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem. 2008;283(40):27200- 27207.
44. de Oliveira MB, Fook-Alves VL, Eugenio AIP, et al. Anti-myeloma effects of ruxoli- tinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. Cancer Lett. 2017;403:206-215.
1228
haematologica | 2018; 103(7)